Table 1. Patient characteristics.
| Characteristics | N | % |
|---|---|---|
| Gender | ||
| Women | 5 | 30 |
| Men | 12 | 70 |
| Type of surgery | ||
| Gross total resection | 10 | 59 |
| Partial resection | 7 | 41 |
| Histology | ||
| IDHwt glioblastoma | 17 | 100 |
| MGMT promoter | ||
| Methylated | 1 | 11 |
| Unmethylated | 8 | 89 |
| First line treatment | ||
| Radiotherapy alone | 1 | 6 |
| Temozolomide alone | 1 | 6 |
| Stupp protocol | 15 | 88 |
| Before bevacizumab + BCNU treatment | ||
| Age (years: median, range) | 62,5 (42,5-89,8) | |
| Body Mass Index (median, range) | 24,1 (18,1-32,1) | |
| Delay between initial diagnosis and relapse (months: median, range) | 13,3 (4,1-64,7) | |
| Karnofsky Performans Status (median) | 70 | |
| 60 | 3 | 19 |
| 70 | 6 | 37 |
| 80 | 3 | 19 |
| 90 | 4 | 25 |
| Patients under steroid | 8 | 47 |
| Tumor diameter* (mm: median, range) | 45 (20-80) | |
Wt : wild-type
* Diameter of contrast enhancement